Jazz Pharmaceuticals plc (NASDAQ: JAZZ) started the day on Thursday, with a price increase of 3.66% at $141.71, before settling in for the price of $136.71 at the close. Taking a more long-term approach, JAZZ posted a 52-week range of $95.49-$148.06.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -1.00%. Meanwhile, its Annual Earning per share during the time was -1.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -62.01%. This publicly-traded company’s shares outstanding now amounts to $60.74 million, simultaneously with a float of $57.84 million. The organization now has a market capitalization sitting at $8.61 billion. At the time of writing, stock’s 50-day Moving Average stood at $133.84, while the 200-day Moving Average is $122.07.
Jazz Pharmaceuticals plc (JAZZ) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Jazz Pharmaceuticals plc’s current insider ownership accounts for 4.81%, in contrast to 100.84% institutional ownership. According to the most recent insider trade that took place on Oct 03 ’25, this organization’s Director sold 3,500 shares at the rate of 140.00, making the entire transaction reach 490,000 in total value, affecting insider ownership by 408,826. Preceding that transaction, on Oct 01 ’25, Company’s Director sold 2,000 for 131.78, making the whole transaction’s value amount to 263,560. This particular insider is now the holder of 412,326 in total.
Jazz Pharmaceuticals plc (JAZZ) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.64 per share during the current fiscal year. Jazz Pharmaceuticals plc’s EPS decrease for this current 12-month fiscal period is -62.01% and is forecasted to reach 22.52 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 5.71% through the next 5 years, which can be compared against the -1.00% growth it accomplished over the previous five years trading on the market.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
Let’s observe the current performance indicators for Jazz Pharmaceuticals plc (JAZZ). It’s Quick Ratio in the last reported quarter now stands at 1.44. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.07. Similarly, its price to free cash flow for trailing twelve months is now 6.44.
In the same vein, JAZZ’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -6.07, a figure that is expected to reach 6.41 in the next quarter, and analysts are predicting that it will be 22.52 at the market close of one year from today.
Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)
If we take a close look at the recent performances of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), its last 5-days Average volume was 1.06 million that shows progress from its year to date volume of 0.9 million. During the previous 9 days, stock’s Stochastic %D was recorded 60.05% While, its Average True Range was 65.83.
Raw Stochastic average of Jazz Pharmaceuticals plc (JAZZ) in the period of the previous 100 days is set at 91.84%, which indicates a major rise in contrast to 79.84% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 4.74 that was higher than 3.29 volatility it exhibited in the past 100-days period.
